BioMarin (BMRN) Q1 2026 Earnings Transcript

BioMarin raised 2026 total revenue guidance to $3.825 billion-$3.925 billion, with midpoint growth now expected at about 20% after closing the Amicus acquisition. Enzyme therapies guidance was increased to $2.725 billion-$2.775 billion, while non-GAAP EPS guidance was updated to $4.85-$5.05 despite slight full-year dilution from Amicus. Q1 revenue was $766 million and non-GAAP EPS was $0.76, with strong demand in enzyme therapies and Voxogo, plus upcoming catalysts from Voxogo and BMN 401 pivotal readouts.

Analysis

BMRN is becoming a cleaner growth comp, but the market may underappreciate how much of the near-term re-rate is now a timing story rather than a step-change in underlying demand. The second half concentration means the stock can look “expensive” on trailing or even Q2 numbers if investors anchor to the weak seasonal print; that creates a setup where any incremental evidence of integration execution or order normalization can reprice the multiple quickly into the Q3/Q4 window. The bigger second-order effect is that the Amicus assets appear to shift BMRN from a single-asset growth narrative into a portfolio that can absorb pipeline volatility, which should lower the discount rate if management can prove repeatable cross-selling and diagnosis expansion.

The most interesting contrarian angle is that the most obvious bull case on Galafold/Pombility is not the revenue bridge alone, but the diagnostic funnel. If BioMarin can use its broader rare-disease commercial infrastructure to convert undiagnosed Fabry patients, the addressable market expands without needing heroic share gains; that makes the implied peak-sales discussion more important than the 2026 guide. On the Pompe side, switching economics tend to be slower and evidence-driven, so the uplift is likely back-end loaded and more durable once it starts—meaning early adoption metrics matter far more than first-year revenue contribution.

Risks are clustered in the next 1-2 quarters: integration slippage, any surprise dilution in Amicus economics, and a pipeline miss in either Voxogo hypochondroplasia or BMN 401. The Naglazyme manufacturing charge looks non-recurring, but it highlights operational fragility; if another supply/process issue emerges, the market will punish the multiple because the new guidance already assumes a smoother execution path in H2. Conversely, positive Voxogo data could create a double-catalyst effect: upside to the core growth engine and a read-through that BMRN’s commercial flywheel works across indications, justifying a premium multiple.

Key Decisions for Investors

• Long BMRN on any post-earnings consolidation for a 3-6 month move into the H2 revenue inflection; target is multiple expansion as investors gain confidence in the Amicus integration and pipeline catalysts, with stop-loss on evidence of integration delay or missed H2 order ramp.
• Buy BMRN Jan-2027 or Jan-2028 calls against a partially funded downside hedge (e.g., collars) to express the view that the market is underestimating the 2027 accretion step; risk/reward improves if management confirms peak-sales upside next quarter.
• Pair trade: long BMRN / short FOLD over the next 1-2 quarters to express that the combined platform value accrues more to the acquirer than the acquired standalone, especially if cross-selling and geographic expansion data come in strong.
• Avoid chasing the stock ahead of the Q2 update; use that event as the key catalyst checkpoint because it should contain the first hard numbers on synergies, peak-sales ambition, and integration cadence—this is where the stock can either rerate or de-rate quickly.
• If Voxogo hypochondroplasia data disappoints, trim or hedge BMRN immediately; that readout is the cleanest catalyst for sentiment reversal because it affects both the core pipeline valuation and the credibility of the broader rare-disease growth story.